Skip to main content
. 2025 Jan 29;12(2):167. doi: 10.3390/children12020167
ICS Inhaled Corticosteroid
GERD Gastroesophageal Reflux Disease
OSA Obstructive Sleep Apnea
PEF Peak Expiratory Flow
LABA Long-Acting Beta2-Agonist
GINA Global Initiative for Asthma
FeNO Fractional Exhaled Nitric Oxide
T2 Type 2
IL Interleukin
IgE Immunoglobulin E
FDA Food and Drug Administration
EMA European Medicines Agency
AIFA Agenzia Italiana Del Farmaco (Italian Medicines Agency)
Q4W Every Four Weeks
Q2W Every Two Weeks
ACQ-7 Asthma Control Questionnaire 7
FEV1 Forced Expiratory Volume in 1 Second
FVC Forced Vital Capacity
EF25–75% Forced Expiratory Flow 25–75%
Th2 T-helper 2 (Cells)
T2-high Type 2 High (Phenotype)
T2-low Type 2 Low (Phenotype)
IL-5 Interleukin-5
RCT Randomized Controlled Trial
C-ACT Childhood Asthma Control Test
OFC Oral Food Challenge
NOAEL No Observed Adverse Effect Level
BDP Beclometasone Dipropionate
PK Pharmacokinetics
PD Pharmacodynamics
TSLP Thymic Stromal Lymphopoietin
IL-13 Interleukin-13
JAK Janus Kinase